Nuage Therapeutics is a biotech spin-off that has developed an innovative technology to study intrinsically disordered proteins (IDPs) for the development of a new generation of transformative therapies. This strategy opens a new avenue for designing therapies targeting proteins that were previously considered undruggable.

“What sets us apart is that we have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules,” explains Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, in this interview. The company’s patented platform enables deeper insight into the transient structures adopted by IDPs. This allows researchers to design drugs capable of recognizing and acting on them—something that was previously impossible. This discovery represents a paradigm shift in drug discovery, turning protein “disorder” into a therapeutic opportunity.

The company, founded by researchers from IRB Barcelona and ICREA, combines cutting-edge basic research with a strong translational focus. Since its inception, Nuage Therapeutics has been committed to building a robust technological platform capable of identifying and characterizing interactions in intrinsically disordered proteins with unprecedented precision. “At the beginning, we sought external support to implement technologies, thinking they would provide all the knowledge and expertise. However, we later realized that we ourselves have contributed a great deal of knowledge about this specific type of protein,” the researcher states.